Training

Strategic agreement BFS-Axentiva for the training of professionals in sustainable innovation in health



ceo de axentiva y ceo de bfs estrechando mano

The consulting firm Axentiva, headquartered in Barcelona, and the business school Barcelona Finance School (BFS), the finance school of the Institute of Financial Studies, have signed a strategic agreement, the result of a shared vision that Barcelona should consolidate itself as a benchmark for the development of sustainable innovation in health.

Together, they are implementing a crucial training line to equip healthcare professionals and entrepreneurs with the necessary knowledge to effectively carry out the economic, clinical, and humanistic evaluation of high-value innovations, helping their integration into the healthcare system.

“The purpose of this course is to equip participants with a complete economic-financial vision of the development of health technologies, accelerating and facilitating their launch to the market or their licensing in the health field. In addition, the course focuses on conducting a thorough analysis of the cost and efficiency of these technologies, providing participants with the necessary tools to assess the viability and impact of the products. In this way, it ensures that investments made generate tangible and justified benefits, allowing professionals to make informed and strategic decisions that drive innovation and improve the quality of healthcare.”

The economic aspects of health are becoming increasingly important in the discovery of health technologies (drugs, devices, or digital health technologies – e.g. apps). The pharmaceutical and medical device industry invests heavily in research and development, but increasingly uses open development systems to incorporate new therapies. It is crucial to understand the evaluation requirements of a new health technology from the earliest stages of development, using tools such as Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA). This will allow us to anticipate the economic impact, the value of the technology, and assess the potential profitability. Whether we opt for organic development, which involves assuming all direct and indirect costs, or prefer to license the technology, it will be essential to carry out cost-effectiveness and sensitivity analyses to make informed decisions and ensure efficiency in the use of public resources. Presenting economic results clearly and understandably to all stakeholders will facilitate decision-making in the development and implementation of new health technologies.

Importance for Barcelona

Barcelona has established itself as a European benchmark hub in health, biotechnology, and entrepreneurship. The city is home to renowned hospitals and research centers, such as Hospital Clínic and ISGlobal, which lead in medical advances. Its biotechnology sector, with institutions such as the Barcelona Science Park and BIST, fosters innovation. In addition, Barcelona stands out for its startup community and support for innovation, with programs such as Barcelona Activa and international events like the Mobile World Congress. These combined factors drive Barcelona as a dynamic and creative center in these key sectors.


This program adds value to Barcelona’s health and entrepreneurship ecosystem.

“This agreement is a crucial step to consolidate synergies in the city of Barcelona as a center of excellence in the economic evaluation of health projects, in the field of the city’s health and entrepreneurship ecosystem,” said Ferran Teixes, general director of the Barcelona Finance School.

Program with an innovative methodology

The program will cover all facets of economic evaluation and modeling, from the basics to the most advanced techniques used in the economic evaluation analysis of health technologies, in accordance with legislative requirements, reimbursement requirements, and with the Joint Clinical Assessment (JCA). Being another essential element of the city’s financial and entrepreneurship hub, such as Biocat Barcelona activa, ACCIÓ, among others.

“Our collaboration with the Barcelona Finance School will allow us to develop a program that will not only benefit individual professionals, but will also contribute to the growth of the innovation ecosystem and the efficiency of the health system in general,” said Carlos Crespo, CEO of Axentiva Solutions.

For the development of the program, a proprietary methodology (M.I.R.E) focused on health innovation will be applied:

  • MAGNITUDE: The target therapeutic market is a critical consideration in the early stages of health technology development. It is about evaluating the current market and the potential market for the new health technology, in line with potential future competitors. It is key to answer: What are our target patients like and how are they being treated?
  • BUDGET IMPACT: Economic modeling is a valuable tool in the early stages of health technology development as it allows companies to simulate the evolution of the potential market and the economic impact of the health technology, as well as the appropriate price for its market entry. It allows us to know: At what price is the investment profitable? How does the price impact health budgets?
  • RELEVANCE: Understanding the burden of disease is essential as it allows not only to assess the impact of the disease on patients and society, but also the additional clinical benefit over what already exists that the new technology may have (therapeutic success, Quality-Adjusted Life Years –QALY–, …). This strategic pillar tries to answer: What additional clinical benefit is expected? What therapeutic, diagnostic, or care need does the new technology cover?
  • EFFICIENCY: The cost-effectiveness ratio of a new technology is critical in development, as it identifies the potential value for the health system in economic and clinical terms, and the potential price affordable by the market. It is about evaluating the additional cost of the technology compared to its additional effectiveness in treating a patient. Finally, it must be assessed: to what extent is it worth betting on the new technology? In other words, is the marginal clinical benefit greater than its marginal cost.

Renowned experts

The training will be given by recognized experts in the field of health economics and project evaluation, ensuring high-quality learning:

  • Carlos Crespo, PhD, in addition to being CEO of Axentiva Solutions, is a professor of biostatistics and experimental design at the University of Barcelona; and a professor of health economics and pharmacoeconomic modeling at Pompeu Fabra University. In addition to his academic career, he has more than 25 years of experience in the development of socio-health research with all types of technologies. His extensive experience has led him to lead multiple national and international projects in the health field, focusing on demonstrating the value of innovation to health systems by applying cutting-edge research methodologies such as economic evaluations, budget impact studies, indirect comparisons, and artificial intelligence. Carlos Crespo, PhD, is a recognized national and international expert in the field of health economics who has published in numerous scientific journals and forums.
  • Jesús Cuervo, PhD (Cum Laude) is an international expert in the design of clinical studies that comprehensively evaluate the marginal benefits of health technologies, including primary clinical objectives along with patient- and caregiver-reported measures. Since 2005, in addition to developing economic evaluations of health technologies in various pathologies, he has conducted multiple psychometric studies for the development and validation of instruments to rigorously collect patients’ health-related quality of life (PROMs) and their experience (PREMs). An expert in innovation and health management, he was one of the pioneers in our country in conducting multi-criteria decision analysis studies for informed health decision-making.
  • Laura Sampietro Colom PhD, MD, is deputy director of innovation and head of the innovation evaluation unit at Hospital Clínic de Barcelona and president of AQuAS (Agency for Health Quality and Assessment of Catalonia). With more than 30 years of experience in the evaluation of innovative health technologies (Health Technology Assessment, HTA), she has been founder and president of the international Health Technology Assessment (HTAi) and president of its Global Policy Forum on Health Technology Assessment. Throughout her career, she has participated in international and European HTA projects and has advised agencies such as WHO and PAHO. She has coordinated initiatives such as AdHopHTA, the first EU-funded project on hospital HTA, and has worked on the evaluation of various health technologies at Hospital Clínic de Barcelona. Laura Samprieto-Colom is a trained physician, specialist in Preventive Medicine and Public Health, and holds a doctorate in Medicine and Surgery. She also has a master’s degree in Public Health and an executive master’s in Innovation and Science Management. Her work focuses on the development and transfer of information to design strategies and policies in the evaluation and access to innovative health technologies.
  • Marcelo Soto, PhD, is an internationally renowned economist with extensive professional experience in economic evaluation and policy analysis. He is currently a senior researcher in health economics at the innovation evaluation unit of Hospital Clínic de Barcelona. Marcelo Soto, PhD, has been Economic Advisor at the Permanent Delegation of Chile to the OECD in France, where he represented Chile on economic, health, and statistics issues, and participated in the development of policy recommendations. Previously, he worked as a senior researcher at the Institute of Economic Analysis in Spain and as a research assistant at the OECD Development Centre. He has published numerous articles in academic journals, standing out in health economics and economic development. His work was recognized, placing him among the top 5% of the most cited authors in economics worldwide.

Conclusion

This initiative underlines the commitment of BFS and Axentiva with Barcelona to innovation and excellence in the health sector. With the implementation of this training line, the city will have one more piece to lead the way in the economic evaluation of health projects, ensuring that the most valuable innovations are effectively integrated into the health system.